Document:

EX-10.25

 Exhibit 10.25 
  

 
 9/27/2013 
 Vivian Doelling

 209 Whisperwood Drive 
 Cary, NC 27518 

Dear Vivian: 
 SCYNEXIS, Inc. (the “Company”) is
pleased to offer you the position of Vice President, Animal Health reporting to Yves Ribeill. In addition to a monthly salary of $17,500, you will receive a stock option entitling you to purchase up to 100,000 shares of the common stock of SCYNEXIS,
Inc. at a price to be confirmed by the Board of Directors. The award of this stock option is subject to approval of the Board of Directors of the Company. You will also be eligible to participate in the team bonus program of the Company and receive
up to a 30 percent bonus. 
 We are also offering you four weeks of paid vacation, access to the Company’s 401(k) retirement plan which features a
Company matching contribution and a comprehensive benefits package. 
 This offer is contingent on the result of a pre-employment physical examination,
including a drug screening, and a pre-employment background check, your agreement to the terms and conditions attached to and incorporated into this letter as Schedule A and your execution of the Company’s standard Nondisclosure, Inventions and
Non-Competition Agreement, a copy of which is enclosed with this letter agreement. This offer is also contingent on your providing sufficient evidence of your legal right to work. This offer is valid through 9/30/2013. 

SCYNEXIS has grown into one of the leading drug discovery companies over the past thirteen years through the dedication and achievement of our employees. To
continue this growth and fully realize our vision, we are continually recruiting motivated and well-trained associates such as yourself. We look forward to your response and hope you will become a part of our team. 

Please do not hesitate to contact me at 919-544-8663 if you have any questions. 

Best regards, 
 /s/ Amanda Mancuso 

Amanda Mancuso, PHR 
 Chief of Staff 

SCYNEXIS, Inc. 
 After consideration, if you choose to accept
this offer, please complete and sign the section below and return it to Anna Brawner at SCYNEXIS, Inc., PO Box 12878, Research Triangle Park, NC 27709-2878. 

I, Vivian Doelling, accept this offer of employment including the attached Schedule A with a start date of 10/17/13. 

 

					
	 /s/ Vivian Doelling
	 		  	9/30/13
	Signature	 		  	Date

 P.O. BOX 12878 — RESEARCH TRIANGLE PARK, N.C. 27709 — TEL: 919 544-8600 — FAX: 919 544 8697 

 Schedule A 

As a Company employee, you will be eligible to enroll in the employee benefit plans and programs maintained by the Company in accordance with the terms of
such plans and programs. The Company has the right to modify, amend or terminate any such plans and programs at any time in its discretion. The terms and conditions for any stock option will be set forth in a Stock Option Agreement between you and
the Company and the Company’s Stock Option Plan. 
 This letter agreement is not intended to, nor does it create any employment contract for any
specified term or duration between you and the Company. Your employment with the Company is terminable at any time, by yourself upon two weeks written notice, or by the Company upon two weeks written notice or salary in lieu thereof. The Company may
also terminate your employment for cause at any time without advance written notice. 
 Upon termination of your employment with the Company and prior to
your departure from the Company, you agree to submit to an exit interview for the purposes of reviewing this letter agreement, the enclosed Nondisclosure, Inventions and Non-Competition Agreement and the trade secrets of the Company, and
surrendering to the Company all proprietary or confidential information and articles belonging to the Company. 
 As you are aware, your employment by the
Company is a full-time employment and you will be required to devote, during regular business hours, all your working time to the business of the Company and not to engage in any other business or private services to any other business either as an
employee, officer, director, agent, contractor or consultant, except with the express written consent of the Company. You will hold in a fiduciary capacity for the benefit of the Company all information with respect to the Company’s finances,
sales, profits, and other proprietary and confidential information acquired by you during your employment. In furtherance of this condition of your employment, we would kindly request that you sign the enclosed Nondisclosure, Inventions and
Non-Competition Agreement. 
 By your signature on the offer letter acceptance, you represent and warrant to the Company that you are not subject to any
employment, noncompetition or other similar agreement with a former employer or otherwise that would prevent or interfere with the Company’s employment of you on the terms set forth herein. 

This letter agreement (including Schedule A), the Nondisclosure, Inventions and Non-Competition Agreement and all ancillary agreements
(collectively, the “Agreements”) shall be governed by the laws of the State of North Carolina. The Agreements constitute the entire agreement between the Company and you, and supersede any and all previous oral or written representation,
communication, understanding or agreement between us. Any and all changes or amendments to the Agreements shall be made in writing and signed by the parties. 

Upon your acceptance by returning the signed letter agreement, the signed Schedule A and the Nondisclosure, Inventions and Non-Competition
Agreement to the Company, this letter agreement (including Schedule A) and the Nondisclosure, Inventions and Non-Competition Agreement shall become binding upon you and the Company. 

 

	
	Agreed to and Accepted:
	
	 /s/ Vivian Doelling

	Signature
	
	 9/30/13

	DateEX-10.26

 Exhibit 10.26 

EXECUTION COPY 
 BOARD
OBSERVATION RIGHTS AGREEMENT 
 This Board Observation Rights Agreement (this “Agreement”) is made and entered into as
of 5 March 2013 (the “Effective Date”) by and between Sanofi, a French Société Anonyme (“Sanofi”), and Scynexis, Inc,, a Delaware corporation (“Scynexis”, together with Sanofi,
the “Parties”). 
 RECITALS 

WHEREAS, Sanofi and HSBC Bank USA. National Association (“HSBC”) entered into that certain Stand-Alone First Demand
Guarantee, dated as of April 9, 2010, as subsequently amended (the “Guarantee”), whereby Sanofi guaranteed the loan; 

WHEREAS, the Parties entered into that certain Reimbursement Agreement; General Security Agreement dated as of April 9, 2010 (the
“Security Agreement”); 
 WHEREAS, Scynexis has requested that Sanofi amend and extend the Expiration Date of the Guarantee
(as defined therein) to and including 30 January 2015; 
 WHEREAS, Sanofi is willing to amend and extend the Expiration Date of the
Guarantee, subject to the terms of that certain Guarantee Extension Agreement dated as of 5 March 2013, by and between Parties (the “GEA”); 

WHEREAS, in consideration of the amendment and extension of the Guarantee, Sanofi requires that Scynexis obtain all necessary consents to
grant and shall subsequently grant Sanofi and Merial Limited (“Merial”) board observation rights; 
 WHEREAS, Merial is the
Animal Health Division of Sanofi; 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Parties agree as follows: 
 SECTION 1. RIGHTS GRANTED 

As consideration for the amendment and extension of the Guarantee, Scynexis hereby grants Sanofi the following rights: 

 

	 	A.	Additional Observer Rights. In addition to the contractual board observer rights Sanofi shall be entitled to in Section 1.B. below, Sanofi shall be entitled to receive and Scynexis shall furnish:
(a) nonpublic financial information about Scynexis; (b) the same financial information as set forth in Sections 3.1(a), (b) and (c) of that certain Fourth Amended and Restated Investor Rights Agreement of
Scynexis dated as of 5 March 2013 (the “Fourth Amended and Restated Investor Rights Agreement”); and (c) inspection rights equivalent to the rights set out in Section 3.2 of the Fourth Amended and Restated
Investor Rights Agreement. 

  
 1. 

	 	B.	Sanofi Observer. Until the later of (i) all obligations of Sanofi under or in connection with the Guarantee (whether current, future, actual or contingent) irrevocably terminating and (ii) Sanofi having
been irrevocably indemnified (by cash payment) in full by Scynexis for all amounts Sanofi shall have paid (if any) under or in connection with the Guarantee, Scynexis shall invite Sanofi, and Sanofi shall have the right, but not the obligation, to
designate one (1) individual who shall be reasonably acceptable to Scynexis, which consent shall not be unreasonably withheld, conditioned, or delayed (the “Sanofi Observer”) to attend in a nonvoting observer capacity all
meetings of the Board of Directors of Scynexis (the “Scynexis Board”), provided that, Sanofi will exercise reasonableness when deciding whether to send such Sanofi Observer to any meeting of the Scynexis Board taking
into consideration available meeting space, and in connection therewith, Scynexis shall give the Sanofi Observer copies of all notices, minutes, consents and other materials, financial or otherwise, which Scynexis provides to the Scynexis Board;
provided, however, that Scynexis reserves the right to exclude the Sanofi Observer from access to any material or meeting or portion thereof if Scynexis believes upon advice of counsel that such exclusion is reasonably necessary to
preserve the attorney-client privilege between Scynexis and its counsel, to protect highly confidential information, or if the information relates to a transaction or arrangement with a third party whose business is competitive with the business of
Sanofi or its affiliates and the Scynexis Board reasonably determines that it is in the best interest of Scynexis to withhold such information from Sanofi Observer; provided that such exclusion of the Sanofi Observer is to the minimum
extent required to preserve the attorney-client privilege, to protect highly confidential information, or to protect competitive third parties interests, as applicable. 

 

	 	C.	 Confidentiality. Sanofi Observer agrees to use, and to use the same degree of care that Sanofi Observer uses to protect its own confidential
information and to keep confidential any information furnished to it pursuant to Sections 3.1 and 3.2 of the Fourth Amended and Restated Investor Rights Agreement that Scynexis identifies as being confidential or proprietary (so
long as such information is not in the public domain), except that Sanofi Observer may disclose such proprietary or confidential information to any subsidiary, affiliate or parent of Sanofi as long as such subsidiary, affiliate or parent is advised
of the confidentiality provisions of this Section 1.C. Sanofi Observer shall have no obligations of confidentiality or non-use with respect to information (i) at such time as it enters the public domain through no fault of Sanofi
Observer; (ii) that is communicated to it by a third party free of any obligation of confidentiality to Scynexis known to Sanofi Observer; or (iii) that is developed by Sanofi Observer or its agents independently of and without reference
to any confidential information communicated by Scynexis. Without limiting the foregoing, the Sanofi Observer may disclose all information provided to the Sanofi Observer in connection with the Sanofi Observer’s rights under this Agreement to
Sanofi and to any subsidiary, parent or affiliate of Sanofi, provided that, Sanofi Observer may not disclose any information provided to it that Scynexis identifies as being confidential or proprietary (unless the addressee of the
disclosure is advised of the confidentiality provisions of this Section 1.C.), except to the extent required to be disclosed by law, court order, or regulatory process, (but solely to the extent such information

  
 2. 

	 	
has not otherwise been disclosed by Scynexis to Sanofi’s shareholders as a result of its ongoing business relationship). Nothing in this Agreement shall prevent disclosure to any stock
exchange, subsidiary, affiliate, parent, attorney, tax authority, financial, antitrust, trade or life science regulator, auditor, or accountant of Sanofi or of any subsidiary thereof. Sanofi and the Sanofi Observer shall have no fiduciary duty,
including, without limitation, a duty of loyalty or care, to Scynexis or any shareholder of the Company, under Delaware law or otherwise, with respect to or arising from Sanofi’s and the Sanofi Observer’s rights and position as a board
observer or receipt of information from Scynexis. Notwithstanding any other provision in this Agreement, the obligation of confidentiality and non-use of this Section 1.C. shall only apply to information which in the reasonable judgment
of Scynexis and Sanofi from content and circumstances is confidential. 

  

	 	D.	Termination. The rights described in this Agreement shall terminate and be of no further force or effect upon the later of: (a) the first date that Sanofi and Sanofi’s affiliates no longer hold any
shares of Scynexis’s stock (or shares of Scynexis’s stock issued upon conversion thereof) or (b) Sanofi no longer has any obligations under the Guarantee and Scynexis no longer has any obligations under the Security Agreement. In
addition, Sanofi shall have the right to replace or terminate Sanofi Observer any time, without prior notice to Scynexis, and without cause. The confidentiality provision of this Agreement shall survive any termination for five (5) years.

 SECTION 2. REPRESENTATIONS AND WARRANTIES 

Scynexis represents and warrants to Sanofi as of the Effective Date that the following statements are true and correct in all material
respects: 
  

	 	A.	Corporate Power and Authority. Scynexis has all requisite power and authority to enter into this Agreement and to carry out the transactions contemplated by this Agreement. 

 

	 	B.	Authorization of Agreements. The execution and delivery of this Agreement by Scynexis has been duly authorized by all necessary action on the part of Scynexis. 

 

	 	C.	Necessary Consents. All necessary consents, approvals, waivers, instruments, amendments, registrations, and authorizations of all governmental authorities and other Persons, including, without limitation, the
Scynexis Board and shareholders of Scynexis, in connection with this Agreement have been obtained. 

  

	 	D.	 No Conflict. The execution, delivery and performance of this Agreement by Scynexis does not and will not: (i) violate: (A) any
provision of any law or any governmental rule or regulation applicable to Scynexis; (B) the certificate or articles of incorporation or partnership agreement or other agreements by which Scynexis is bound, other constitutive documents or
by-laws of the Scynexis; or (C) any order, judgment or decree of any court or other agency or government 

  
 3. 

	 	
binding on the Scynexis; (ii) conflict with, result in a breach or constitute (with or without due notice or lapse of time or both) a conflict, breach or default under any Contractual
Obligation of Scynexis, except to the extent such conflict, breach or default could not reasonably be expected to have a Material Adverse Effect, or has otherwise been specifically waived by Sanofi, in writing; or (iii) require any approval of
stockholders, directors, members or partners or any approval or consent of any Person under any Contractual Obligation of Scynexis, except for such approvals or consents which will be obtained on or before the Effective Date and disclosed to Sanofi,
and except for any such approvals or consents the failure of which to obtain will not have a Material Adverse Effect. 

 For
the purposes of this Agreement, “Person” shall mean any individual, corporation, limited liability company, partnership, joint venture, joint stock company, trust, land trust, business trust, employee benefit plan or trust,
unincorporated organization or ether entity. For the purposes of this Agreement, “Material Adverse Effect” shall mean (a) a material adverse change in, or a material adverse effect upon, the assets, properties, operations,
business, or condition (financial or otherwise) of Scynexis, (b) a material impairment of the ability of Scynexis or an affiliate of Scynexis to perform under any Loan Document (as defined below) to which it is a party, or (c) a material
adverse effect upon the legality, validity, binding effect, or enforceability against Scynexis of any Loan Document to which it is a party. For the purposes of this Agreement, “Contractual Obligations” shall mean as to any Person,
any provision of any security issued by such Person or of any agreement, undertaking, contract, indenture, mortgage, deed of trust or other instrument or arrangement (whether in writing or otherwise) to which such Person is a party or by which it or
any of such Person’s property is bound. For the purposes of this Agreement, “Loan Documents” shall mean the Security Agreement, the GEA, that Credit Agreement by and between HSBC and Scynexis, dated as of April 9, 2010
(the “Credit Agreement”), as in effect at any given time, that certain Board Observation Rights Agreement, by and between Merial and Scynexis, dated as of     March 2013 (the “Merial BORA”) and
this Agreement. 
  

	 	E.	Binding Obligation. This Agreement has been duly executed and delivered by Scynexis and the Agreement is the legally valid and binding obligation of Scynexis, enforceable against Scynexis in accordance with its
respective terms. 

  

	 	F.	Absence of Default. No event has occurred and is continuing or will result from the consummation of the transactions contemplated by this Agreement that would constitute an Event or Default or Default (as defined
in the Facility). 

 SECTION 3. MISCELLANEOUS 
  

	 	A.	Governing Law. This Agreement shall be governed by and construed exclusively in accordance with the laws of the State of North Carolina, without giving effect to applicable principles of conflicts of laws
thereof. 

  
 4. 

	 	B.	Notices. All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given or made as of the date delivered or mailed if delivered in person, by telecopy, cable,
telegram or telex, or by registered or certified mail (postage prepaid, return receipt requested) to the respective parties as follows: 

if to Sanofi: 
 Sanofi 

54 rue La Boétie 
 75008
Paris, France 
 Attention: Marie Debans; Corinne Cervantes; Alexander de Daranyi 

with a copy to: 
 Life Sciences
Law 
 870 Martin Luther King, Jr. Blvd. 

Chapel Hill, NC 27514 
 Attention:
Sheila Mikhail 
 if to Scynexis: 

3501C Tricenter Boulevard 

Durham, North Carolina 27713 

Attn: Yves Ribeill, Ph.D. 

President and Chief Executive Officer 

Tel: (919) 544-8600 
 Fax:
(919) 544-8697 
  

	 	C.	Indemnity. Without prejudice to the provisions of Section 1.C. and without creating any implication that observer owes any fiduciary duties of any kind, including, without limitation, a duty of
loyalty or care, to Scynexis, its shareholders, its affiliates and other related Persons or any other person or entity, Scynexis shall, to the maximum extent legally permissible, indemnify, defend and hold harmless each and every person who may
serve or who has served at any time as a Sanofi Observer against any and all losses, costs, expenses and liabilities of any type, kind or nature, including, without limitation, counsel fees and expenses, judgments, fines, excise taxes, penalties and
settlement payments, or other costs, incurred by or imposed upon such person in connection with any threatened, pending or completed action, suit or proceeding, whether in law or in equity, in which he or she may become involved as a result of, by
virtue of being a Sanofi Observer, or by reason of his or her service in such capacity. 

 The indemnification provided
hereunder shall inure to the benefit of the heirs, executors and administrators of persons entitled to indemnification hereunder. The right of indemnification under this Section 3.C. shall be in addition to and not exclusive of all other
rights to which any person may be entitled. 

  
 5. 

 No amendment or repeal of the provisions of this Section 3.C. which adversely affects
the right of an indemnified person under this Section 3.C. shall apply to such person with respect to those acts or omissions which occurred at any time prior to such amendment or repeal, unless such amendment or repeal was voted by or
was made with the written consent of Sanofi. 
  

	 	D.	Counterparts. This Agreement may be executed in one or more counterparts, each of which shall constitute an original agreement, but all of which together shall constitute one and the same agreement.

  

	 	E.	Entire Agreement. This Agreement, and the terms and provisions hereof, constitute the entire understanding and agreement between the Parties hereto with respect to the subject matter hereof and supersedes any and
all prior or contemporaneous amendments or understandings with respect to the subject matter hereof, whether express or implied, oral or written. 

  

	 	F.	Severability. In case any provision in this Agreement shall be invalid, illegal or unenforceable, such provision shall be severable from the remainder of this Agreement and the validity, legality and
enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

  

	 	G.	Further Assurances. The Parties each, at any time or from time to time, shall execute and deliver or cause to be executed and delivered such further assurances, instruments, consents, waivers, or documents as may
be reasonably necessary to fulfill the terms and conditions of this Agreement. The responsible party shall promptly cure any defects in the execution and delivery of the documents evidencing the granting of the board observer rights and immediately
execute and deliver to the other Party all such other and further instruments as may be reasonably required from time to tune in order to satisfy or comply with the covenants and agreements made in this Agreement. 

 

	 	H.	Specific Performance. Irreparable damage would occur if any of the provisions of this Agreement were not performed in accordance with the terms hereof, and the Parties shall be entitled to specific performance of
the terms hereof, in addition to any other remedy at law or equity. 

  

	 	I.	 Venue. SCYNEXIS HEREBY IRREVOCABLY AGREES THAT ANY LEGAL ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN
DOCUMENTS OR TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY SHALL BE BROUGHT EXCLUSIVELY IN THE COURTS OF THE STATE OF NORTH CAROLINA AND HEREBY EXPRESSLY SUBMITS TO THE PERSONAL JURISDICTION AND VENUE OF SUCH COURTS FOR THE PURPOSES THEREOF AND
EXPRESSLY WAIVES ANY CLAIM OF IMPROPER VENUE AND ANY CLAIM THAT SUCH COURTS ARE AN INCONVENIENT FORUM. SCYNEXIS HEREBY IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS OF THE AFOREMENTIONED

  
 6. 

	 	
COURTS IN ANY SUCH SUIT, ACTION OR PROCEEDING BY THE MAILING OF COPIES THEREOF BY REGISTERED OR CERTIFIED MAIL, POSTAGE PREPAID, TO ITS ADDRESS SET FORTH IN SECTION 3.B. OF THIS AGREEMENT,
SUCH SERVICE TO BECOME EFFECTIVE 10 DAYS AFTER SUCH MAILING. 

 [SIGNATURE PAGE FOLLOWS] 

  
 7. 

 IN WITNESS WHEREOF, Scynexis and Sanofi have caused this Agreement to be executed by their
respective duly authorized agents or officers, to be effective as of the Effective Date. 
  

			
	SCYNEXIS, INC.
		
	By:	 	 /s/ Yves Ribeill

	Name: Yves Ribeill
	Title: President and CEO
	
	SANOFI
		
	By:	 	 /s/ Jérôme Contamine

	Name: Jérôme Contamine
	Title: Executive Vice President, Chief Financial Officer

  
 8.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]